Story perspectives

Genetic Breakthrough Offers Hope for Pericytic Tumors

11/1/2025

50 7

Summary

Story summary

Researchers identified actionable BRAF V600D and V600E mutations in unclassified pericytic tumors using the Ion AmpliSeq Comprehensive Cancer Panel and Sanger sequencing.
A newborn with a congenital pericytic tumor regressed after targeted therapy.
The findings support integrating genetic screening into clinical practice for these tumors.
Overall, the work promotes personalized medicine and could transform diagnosis, treatment decisions, and future research.

1 of 1

Story summary

Researchers identified actionable BRAF V600D and V600E mutations in unclassified pericytic tumors using the Ion AmpliSeq Comprehensive Cancer Panel and Sanger sequencing.
A newborn with a congenital pericytic tumor regressed after targeted therapy.
The findings support integrating genetic screening into clinical practice for these tumors.
Overall, the work promotes personalized medicine and could transform diagnosis, treatment decisions, and future research.